Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Development and validation of a quantification method for cucurbitacins E and I in rat plasma: Application to population pharmacokinetic studies

Full text
Author(s):
Lanchoti Fiori, Giovana Maria ; D'Agate, Salvatore ; Rocha, Adriana ; Soares Pereira, Ana Maria ; Della Pasqua, O. ; Lopes, Norberto Peporine
Total Authors: 6
Document type: Journal article
Source: Journal of Pharmaceutical and Biomedical Analysis; v. 144, n. SI, p. 99-105, SEP 10 2017.
Web of Science Citations: 3
Abstract

Cucurbitacin E is a potential drug candidate due to its anticancer activity, recognition of its molecular targets, and synergism with other drugs used for cancer treatment. However, the use of cucurbitacin E in clinical practice is not possible because of important knowledge gaps in its preclinical and clinical pharmacokinetic characteristics. Cucurbitacin E is hydrolyzed to cucurbitacin I in plasma and in human liver microsomes. The aim of this study was to evaluate the population pharmacokinetics of cucurbitacin E and of its metabolite cucurbitacin I in rats. The method for the sequential analysis of cucurbitacins E and I in rat plasma was developed using LC-MS/MS. Plasma aliquots of 50 mu L were deproteinized with acetonitrile and clobazam was added as internal standard. The extracts were injected into an RP-18 column and eluted with a mobile phase consisting of a mixture of acetonitrile:water:methanol (32:35:33, v/v/v). The method was precise and accurate, showing linearity in the range of 1-100 ng cucurbitacin E/mL plasma and of 0.4-200 ng cucurbitacin I/mL plasma. The method was applied to the pharmacokinetic evaluation of cucurbitacin E administered intravenously to male Wistar rats (1 mg/kg). Serial blood samples were collected up to 24 h after administration. The plasma concentrations of cucurbitacin E were quantified up to 16h, while the plasma concentrations of cucurbitacin I remained below the limit of quantification. A population pharmacokinetic model was developed for cucurbitacin E using the NONMEM program, with adequate goodness of fit and predictive performance. The following pharmacokinetic parameters were obtained: release time of 0.45 h, volume of distribution of 27.22 L, clearance of 4.13 L/h, and elimination half-life of 4.57 h. (C) 2017 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 14/50265-3 - Distribution and metabolism of natural and synthetic xenobiotics: from the comprehension of reactional process to tissue imaging generation
Grantee:Norberto Peporine Lopes
Support type: BIOTA-FAPESP Program - Thematic Grants
FAPESP's process: 12/14408-9 - Disposition kinetics, plasma protein binding, metabolism in vitro and in vivo of curcubitacins in rats
Grantee:Giovana Maria Lanchoti Fiori
Support type: Scholarships in Brazil - Doctorate